BioLife Solutions announced Mustang Bio has adopted BioLife's CryoStor cell freeze media and evo cold chain system for use in current and upcoming clinical trials.
After evaluations of various alternatives on the market, Mustang selected BioLife's proprietary CryoStor and evo products to support best biopreservation practices, which focus on maximizing manufacturing yield and quality while reducing distribution-related risks, such as temperature excursions and in-transit shipping damage. The evo cold chain system was added to BioLife's product portfolio via the recently announced acquisition of SAVSU Technologies.
"We appreciate the opportunity to support Mustang's clinical programs,” Mike Rice, BioLife's CEO, said. “Our growing product portfolio is comprised of tools that can reduce the risk of delivering a non-viable dose, and the resulting therapeutic failure and economic loss for cell and gene therapy developers."